Phase 3Recruiting

Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery

Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery

Sponsor
Brigham and Women's Hospital (Academic or other)
Enrollment
100 planned
Conditions
Opioid Consumption, Postoperative; Multimodal Analgesia; Ureteroscopy; Ureteral Stents; Ureteral Stent-Related Symptoms
Interventions
multimodal analgesia regimen without suzetrigine; Suzetrigine
Ages
adults, older adults
Registry
NCT07654296

Full record on ClinicalTrials.gov

From the registry

Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal…

Primary outcomes

  • Post-discharge opioid consumption (MME)

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered